[1]Young KH,Newell P,Cottam B,et al. TGF beta inhibition prior to hypofractionated radiation enhances efficacy in preclinical models[J]. Cancer Immunol Res,2014,2(10):1011-1022.DOI:10.1158/2326-6066.CIR-13-0207. [2]Draghiciu O,Nijman HW,Daemen T. From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors[J/OL]. Clin Dev Immunol,2011,2011:439053[2014-07-10].http://www.hindawi.com/journals/jir/2011/439053/.DOI:10.1155/2011/439053. [3]Hawinkels LJ,Ten DP. Exploring anti-TGF-beta therapies in cancer and fibrosis[J]. Growth Factors,2011,29(4):140-152.DOI:10.3109/08977194.2011.595411. [4]Derynck R,Akhurst RJ. Differentiation plasticity regulated by TGF-beta family proteins in development and disease[J]. Nat Cell Biol,2007,9(9):1000-1004.DOI:10.1038/ncb434. [5]Massagu J,Padua D. Roles of TGF beta in metastasis[J]. Cell research,2009,19(1):89-102.DOI:10.1038/cr.2008.316. [6]Serizawa M,Takahashi T,Yamamoto N,et al. Combined treatment with erlotinib and a transforming growth factor-beta type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells[J]. J Thorac Oncol,2013,8(3):259-269.DOI:10.1097/JTO.0b013e318279e942. [7]Pardali K,Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer[J]. Biochim Biophys Acta,2007,1775(1):21-62: DOI:10.1016/j.bbcan.2006.06.004. [8]Heldin CH,Vanlandewijck M,Moustakas A. Regulation of EMT by TGF beta in cancer[J]. FEBS Lett,2012,586(14):1959-1970.DOI:10.1016/j.febslet.2012.02.037. [9]Devaud C,John LB,Westwood JA,et al. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy[J/0L].Oncoimmunology,2013,2(8):e25961[2014-07-10].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782527/.DOI:10.4161/onci.25961. [10]Huang X,Lee C. From TGF-beta to cancer therapy[J].Durr Drug Targets,2003,4(3):243-250. [11]Katz LH,Li Y,Chen JS,et al. Targeting TGF-beta signaling in cancer[J]. Expert Opin Ther Targets,2013,17(7):743-760.DOI:10.1517/14728222.2013.782287. [12]Liu L,Kron KJ,Pethe VV,et al. Association of tissue promoter methylation levels of APC,TGF beta2,HOXD3 and RASSF1A with prostate cancer progression[J]. Int J Cancer,2011,129(10):2454-2462.DOI:10.1002/ijc.25908. [13]Andarawewa KL,Erickson AC,Chou WS,et al. Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition[J]. Cancer Res,2007,67(18):8662-8670.DOI:10.1158/0008-5472.CAN-07-1294. [14]Morris JC,Tan AR,Olencki TE,et al. Phase I study of GC1008(fresolimumab): a human anti-transforming growth factor-beta(TGF beta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma[J/OL].PLoS One,2014,9(3):e90353[2014-07-10].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949712/.DOI:10.1371/journal.pone.0090353. [15]Cao S,Wu R. Expression of angiotensin II and aldosterone in radiation-induced lung injury[J]. Cancer Biol Med,2012,9(4):254-260.DOI:10.7497/j.issn.2095-3941.2012.04.006. [16]Biswas S,Guix M,Rinehart C,et al. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression[J]. J Clin Invest,2007,117(5):1305-1313.DOI:10.1172/JCI30740. [17]Zhao L,Ji W,Zhang L,et al. Changes of circulating transforming growth factor-beta1 level during radiation therapy are correlated with the prognosis of locally advanced non-small cell lung cancer[J]. J Thorac Oncol,2010,5(4):521-525.DOI:10.1097/JTO.0b013e3181cbf761. [18]Schaue D,Xie MW,Ratikan JA,et al. Regulatory T cells in radiotherapeutic responses[J/OL].Front Oncol,2012,2:90[2014-07-10].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421147/.DOI:10.3389/fonc.2012.00090. [19]Chiang CS,Fu SY,Wang SC,et al. Irradiation promotes an M2 macrophage phenotype in tumor hypoxia[J/OL]. Front Oncol,2012,2:89[2014-07-10].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412458/.DOI:10.3389/fonc.2012.00089. [20]于金明,滕菲菲. 放疗与免疫治疗联合应用的相关机制及研究进展[J]. 中国肿瘤临床,2014(09):547-550.DOI:10.3969/j.issn.1000-8179.20140527. [21]Postow MA,Callahan MK,Barker CA,et al. Immunologic correlates of the abscopal effect in a patient with melanoma[J]. N Engl J Med,2012,366(10):925-931.DOI:10.1056/NEJMoa1112824. [22]Wei S,Egenti MU,Teitz-Tennenbaum S,et al. Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice[J]. J Immunother,2013,36(2):124-132.DOI:10.1097/CJI.0b013e31828298e6. [23]Zeng J,See AP,Phallen J,et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas[J]. Int J Radiat Oncol Biol Phys,2013,86(2):343-349.DOI:10.1016/j.ijrobp.2012.12.025. [24]Suzuki Y,Mimura K,Yoshimoto Y,et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma[J]. Cancer Res,2012,72(16):3967-3976.DOI:10.1158/0008-5472.CAN-12-0851. [25]Sakaguchi S,Miyara M,Costantino CM,et al. FOXP3+ regulatory T cells in the human immune system[J]. Nat Rev Immunol,2010,10(7):490-500.DOI:10.1038/nri2785. [26]Wilson S,Levy D. A mathematical model of the enhancement of tumor vaccine efficacy by immunotherapy[J]. Bull Math Biol,2012,74(7):1485-1500.DOI:10.1007/s11538-012-9722-4. [27]Fu S,Zhang N,Yopp AC,et al. TGF-beta induces Foxp3+ T-regulatory cells from CD4+ CD25-precursors[J]. Am J Transplant,2004,4(10):1614-1627.DOI:10.1111/j.1600-6143.2004.00566.x. [28]Luckheeram RV,Zhou R,Verma AD,et al. CD4(+)T cells: differentiation and functions[J/OL]. Clin Dev Immunol,2012,2012:925135[2014-07-10].http://www.hindawi.com/journals/jir/2012/925135.DOI:10.1155/2012/925135. [29]Kimball AS,Webb TJ. The Roles of Radiotherapy and Immunotherapy for the Treatment of Lymphoma[J]. Mol Cell Pharmacol,2013,5(1):27-38. [30]Strauss L,Bergmann C,Szczepanski M,et al. A unique subset of CD4+CD25 highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment[J]. Clin Cancer Res,2007,13(15 Pt 1):4345-4354.DOI:10.1158/1078-0432.CCR-07-0472. [31]Quatromoni JG,Suzuki E,Okusanya O,et al. The timing of TGF-beta inhibition affects the generation of antigen-specific CD8+ T cells[J/OL].BMC Immunol,2013,14:30[2014-07-10].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725164/.DOI:10.1186/1471-2172-14-30. [32]Donkor MK,Sarkar A,Savage PA,et al. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-beta1 cytokine[J]. Immunity,2011,35(1):123-134.DOI:10.1016/j.immuni.2011.04.019. [33]Takaku S,Terabe M,Ambrosino E,et al. Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells[J]. Int J Cancer,2010,126(7):1666-1674.DOI:10.1002/ijc.24961. [34]Zhang M,Berndt BE,Chen JJ,et al. Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy[J]. J Immunol,2008,181(5):3690-3697. [35]Oh S,Kim E,Kang D,et al. Transforming growth factor-beta gene silencing using adenovirus expressing TGF-beta1 or TGF-beta2 shRNA[J]. Cancer Gene Ther,2013,20(2):94-100.DOI:10.1038/cgt.2012.90. [36]Bouquet F,Pal A,Pilones KA,et al. TGF beta1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo[J]. Clin Cancer Res,2011,17(21):6754-6765.DOI:10.1158/1078-0432.CCR-11-0544. [37]Kawano M,Itonaga I,Iwasaki T,et al. Anti-TGF-beta antibody combined with dendritic cells produce antitumor effects in osteosarcoma[J]. Clin Orthop Relat Res,2012,470(8):2288-2294.DOI:10.1007/s11999-012-2299-2. [38]Yoon JH,Jung SM,Park SH,et al. Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4,thereby derepressing eomesodermin in cytotoxic T lymphocytes[J]. EMBO Mol Med,2013,5(11):1720-1739.DOI:10.1002/emmm.2013.2524. [39]Chang LY,Lin YC,Mahalingam J,et al. Tumor-derived chemokine CCL5 enhances TGF-beta-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells[J]. Cancer Res,2012,72(5):1092-1102.DOI:10.1158/0008-5472.CAN-11-2493. [40]Koido S,Homma S,Okamoto M,et al. Augmentation of antitumor immunity by fusions of ethanol-treated tumor cells and dendritic cells stimulated via dual TLRs through TGF-beta1 blockade and IL-12p70 production[J/OL]. PLoS One,2013,8(5):e63498[2014-07-10].http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0063498.DOI:10.1371/journal.pone.0063498. [41]Formenti S C,Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift[J]. J Natl Cancer Inst,2013,105(4):256-265.DOI:10.1093/jnci/djs629.
2015, Vol. 24 
